醫(yī)學(xué)博士，主任醫(yī)師，北京市優(yōu)秀人才培養(yǎng)資助青年骨干。現(xiàn)任北京大學(xué)腫瘤醫(yī)院胃腸腫瘤中心一病區(qū)副主任（主持工作）。兼任國家腫瘤質(zhì)控中心胃癌質(zhì)控專家委員會委員兼秘書、中國抗癌協(xié)會青年理事會常務(wù)理事、中國抗癌協(xié)會胃癌專業(yè)委員會委員、中國抗癌協(xié)會手術(shù)安全與質(zhì)量控制專委會常務(wù)委員兼秘書長、中國抗癌協(xié)會腫瘤大數(shù)據(jù)與真實世界研究專業(yè)委員會常務(wù)委員、中國臨床腫瘤學(xué)會青年委員、國際胃癌學(xué)會會員。主要研究方向包括胃癌的微創(chuàng)外科與圍術(shù)期綜合治療、外科臨床研究方法學(xué)框架的開發(fā)與應(yīng)用。在手術(shù)視頻資料分析、胃癌?？萍膊?shù)據(jù)庫建設(shè)與質(zhì)量控制等多個臨床實踐的數(shù)據(jù)化工作方面具有豐富經(jīng)驗。在Nature Medcine、JAMA Surgery、Gastric Cancer等領(lǐng)域內(nèi)重要期刊累計發(fā)表各類學(xué)術(shù)文章120余篇，發(fā)表論文在“谷歌學(xué)術(shù)”總引用1970余次（h指數(shù)24）。獲授權(quán)國家發(fā)明專利4項。

代表性成果

1. 胃癌化療后腹腔鏡手術(shù)的隨機(jī)對照研究，是該領(lǐng)域內(nèi)全球首個隨機(jī)對照研究，證明了對于新輔助治療后的進(jìn)展期胃癌患者，腹腔鏡手術(shù)可有效減輕術(shù)后疼痛、降低26%的術(shù)后并發(fā)癥（20% vs. 46%），并提高輔助化療的耐受性。（JAMA Surgery, 2019）

2. 基于計算機(jī)視覺的手術(shù)質(zhì)量評價工具開發(fā)，以胃癌腹腔鏡手術(shù)為切入點，首先開發(fā)了腹腔鏡胃癌手術(shù)質(zhì)量主觀評價工具及胃癌手術(shù)階段及事件標(biāo)注工具，初步建立了胃癌腹腔鏡手術(shù)質(zhì)量主觀評價數(shù)據(jù)集，并在上述工作基礎(chǔ)上，對胃癌腹腔鏡手術(shù)質(zhì)量計算機(jī)評估方法進(jìn)行了初步探索。目前已經(jīng)掌握了多種視頻特征提取及時序模型設(shè)計方法，提出了基于難樣本挖掘的劃分方法和強(qiáng)化學(xué)習(xí)方法，并設(shè)計了手術(shù)器械無監(jiān)督分割方法和基于手術(shù)視野的手術(shù)質(zhì)量客觀評價模型，早期試驗結(jié)果已展現(xiàn)出了該方法的廣闊前景，并多次獲邀在計算機(jī)視覺頂級學(xué)術(shù)會議上進(jìn)行口頭報告，獲得國家發(fā)明專利授權(quán)1項。（MICCAI 2019、MICCAI 2020、CVPR 2021）

PD-1/CTLA-4雙靶點單抗聯(lián)合化療治療晚期胃癌的一線研究，該研究使用國產(chǎn)原研的創(chuàng)新藥物卡度尼利單抗開展國際上首個針對PD-1/CTLA-4雙靶點單抗聯(lián)合化療一線治療晚期胃癌的臨床研究，證明該方案具有良好的安全性和有效性，能夠顯著延長患者的生存期。研究結(jié)果的發(fā)表，為卡度尼利單抗在晚期胃癌一線治療適應(yīng)癥的批準(zhǔn)提供了有力支持。（Nature Medicine, 2024）

發(fā)表論文

1. Li, Z.Y., Tang, L., Li, S.X., Shan, F., Bu, Z.D., & Ji, J.F. (2013). Imatinib mesylate in clinically suspected gastric stromal tumors. Chinese Journal of Cancer Research, 25(5), 600.

2. Liu, Z., Jiang, D., Cai, J., Zong, X., Zhang, J., Shan, F., Wang, W., & Wang, W. (2011). Study of TGF-$β$1 phage model peptides on inhibiting keloid fibroblasts proliferation. Zhonghua yi xue za zhi, 91(38), 2714–2718.

3. Ji, X., Liu, Y.Q., Wu, A.W., Zhang, L.H., Li, Z.Y., Shan, F., Li, X.H., & Ji, J.F. (2011). Expression of human epidermal growth factor receptor 2 in gastroesophageal cancer with different scoring systems and its relationship with clinicopathological features. Zhonghua wei Chang wai ke za zhi= Chinese Journal of Gastrointestinal Surgery, 14(5), 356–359.

4. Bu, Z.D., Zheng, Z.X., Li, Z.Y., Zhang, L.H., Wu, A.W., Wu, X.J., Zong, X.L., Li, S.X., Shan, F., Ji, X., & others (2012). 34. Lymphatic vascular invasion is an independent factor of lymph node metastasis and survival in T2 gastric cancer patients. Tumor Biol.

5. Ji, X., Bu, Z.D., Yan, Y., Li, Z.Y., Wu, A.W., Zhang, L.H., Zhang, J., Wu, X.J., Zong, X.L., Li, S.X., & others (2018). The 8th edition of the American Joint Committee on Cancer tumor-node-metastasis staging system for gastric cancer is superior to the 7th edition: results from a Chinese mono-institutional study of 1663 patients. Gastric cancer, 21, 643–652.

6. Shan, F., & Ji, J. (2014). 第十三章: 胃癌多學(xué)科治療的最新進(jìn)展和爭議. 科研時間, 1(60), 13.

7. Li, Z., Xing, X., Shan, F., Li, S., Li, Z., Xiao, A., Xing, Z., Xue, K., Li, Z., Hu, Y., & others (2016). ABCC2-24C> T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients. Oncotarget, 7(34), 55449.

8. Wu, X.J., Yuan, P., Li, Z.Y., Bu, Z.D., Zhang, L.H., Wu, A.W., Zong, X.L., Li, S.X., Shan, F., Ji, X., & others (2013). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tumor Biology, 34, 463–469.

9. Wu, X.J., Miao, R.L., Li, Z.Y., Bu, Z.D., Zhang, L.H., Wu, A.W., Zong, X.L., Li, S.X., Shan, F., Ji, X., & others (2015). Prognostic value of metastatic lymph node ratio as an additional tool to the TNM stage system in gastric cancer. European Journal of Surgical Oncology (EJSO), 41(7), 927–933.

10. Shan, F., LI, Z.y., BU, Z.d., & others (2011). The analysis of gastric cancer staging AJCC 6th ed. and 7th ed.. Chinese Journal of Practical Surgery.

11. Shan, F., Miao, R., Xue, K., Li, Z., Li, Z., Bu, Z., Wu, A., Zhang, L., Wu, X., Zong, X., & others (2016). Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials. Cancer Letters, 380(2), 598–607.

12. Li, Z., Li, Z., Jia, S., Bu, Z., Zhang, L., Wu, X., Li, S., Shan, F., Ji, X., & Ji, J. (2017). Depth of tumor invasion and tumor-occupied portions of stomach are predictive factors of intra-abdominal metastasis. Chinese Journal of Cancer Research, 29(2), 109.

13. Wu, A.W., Yang, H., Jia, Y.N., Zhang, C.h., Shan, F., Zhang, L.H., Li, Z.Y., Wu, X.J., Zong, X.L., & Ji, J.F. (2012). 19. Ratio of lymph node metastasis and lymphavascular invasion predict diseasespecific survival of proximal gastric adenocarcinoma in Chinese patients following curative resection. Translational Gastrointestinal Cancer.

14. Ji, X., Bu, Z.D., Li, Z.Y., Wu, A.W., Zhang, L.H., Zhang, J., Wu, X.J., Zong, X.L., Li, S.X., Shan, F., & others (2017). Prognostic significance of the total number of harvested lymph nodes for lymph node-negative gastric cancer patients. BMC cancer, 17, 1–9.

15. Li, Z.Y., Shan, F., Zhang, L.H., Bu, Z.D., Wu, A.W., Wu, X.J., Zong, X.L., Wu, Q., Ren, H., & Ji, J.F. (2011). Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer. World Journal of Surgical Oncology, 9, 1–7.

16. Li, Z.Y., Tang, L., Zhang, L.H., Bu, Z.D., Wu, A.W., Wu, X.J., Zong, X.L., Wu, Q., Shan, F., Li, S.X., & others (2010). Weekly docetaxel and cisplatin plus fluorouracil as a preoperative treatment for gastric cancer patients with synchronous multiple hepatic metastases: a pilot study. Medical Oncology, 27, 1314–1318.

17. Ji, X., Yan, Y., Bu, Z.D., Li, Z.Y., Wu, A.W., Zhang, L.H., Wu, X.J., Zong, X.L., Li, S.X., Shan, F., & others (2017). The optimal extent of gastrectomy for middle-third gastric cancer: distal subtotal gastrectomy is superior to total gastrectomy in short-term effect without sacrificing long-term survival. BMC cancer, 17, 1–9.

18. Li, S., Li, Z., Zhang, L., Bu, Z., Wu, A., Wu, X., Zong, X., Shan, F., Ji, X., & Ji, J. (2013). Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk. Zhonghua wei Chang wai ke za zhi= Chinese Journal of Gastrointestinal Surgery, 16(3), 226–229.

19. Yang, H., Wu, A., Li, Z., Bu, Z., Zhang, L., Wu, X., Zong, X., Li, S., Shan, F., Yang, Y., & others (2010). Surgical treatment results and prognostic analysis of 514 cases with gastroesophageal junction carcinoma. Zhonghua wai ke za zhi [Chinese Journal of Surgery], 48(17), 1289–1294.

20. Li, Z., Shan, F., Wang, Y., Zhang, Y., Zhang, L., Li, S., Jia, Y., Xue, K., Miao, R., Li, Z., & others (2018). Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: a meta-analysis. PLoS One, 13(1), e0189294.

21. Shan, F., Li, Z., Bu, Z., Zhang, L., Wu, A., Wu, X., Wu, Q., Zong, X., Li, S., Ji, X., & others (2012). 17. Phase II study of oxaliplatin plus S-1 as neoadjuvant chemotherapy for advanced gastric cancer: Response and safety results. Translational Gastrointestinal Cancer.

22. Shan, F., & Ji, J. (2012). Updating advances and controversies on the multidisciplinary therapy of gastric cancer. Transl Gastrointest Cancer, 1(2), 151–160.

23. JI, J., & Shan, F. (2010). Multidisciplinary management of gastric cancer. Chinese Journal of Digestive Surgery, 241–243.

24. Zhang, Q., Shan, F., Li, Z., Gao, J., Li, Y., Shen, L., Ji, J., & Lu, M. (2018). A prospective study on the changes and clinical significance of pre-operative and post-operative circulating tumor cells in resectable gastric cancer. Journal of Translational Medicine, 16, 1–12.

25. Wang, Y., Li, Z., Shan, F., Miao, R., Xue, K., Gao, C., Chen, N., Gao, X., Li, S., & Ji, J. (2018). Current status of diagnosis and treatment of early gastric cancer in China–Data from China Gastrointestinal Cancer Surgery Union. Zhonghua wei Chang wai ke za zhi= Chinese Journal of Gastrointestinal Surgery, 21(2), 168–174.

26. Li, Z., Fan, B., Shan, F., Tang, L., Bu, Z., Wu, A., Zhang, L., Wu, X., Zong, X., Li, S., & others (2015). Gastrectomy in comprehensive treatment of advanced gastric cancer with synchronous liver metastasis: a prospectively comparative study. World journal of surgical oncology, 13, 1–7.

27. LI, S., LI, Z., Zhang, L., Shan, F., Jia, Y., Xue, K., Miao, R., LI, Z., & JI, J. (2017). Clinical efficacy of laparoscopic vagus nerve and pylorus-preserving gastrectomy for early gastric cancer. Chinese Journal of Digestive Surgery, 298–303.

28. Wu, X., Li, Z., Li, Z., Jia, Y., Shan, F., Ji, X., Bu, Z., Zhang, L., Wu, A., & Ji, J. (2015). Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. Journal of Surgical Oncology, 111(7), 840–847.

29. Xing, X., Guo, J., Ding, G., Li, B., Dong, B., Feng, Q., Li, S., Zhang, J., Ying, X., Cheng, X., & others (2018). Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology, 7(3), e1356144.

30. Zhang, C., Wu, A., Li, Z., Zhang, L., Bu, Z., Wu, X., Zong, X., Li, S., Shan, F., & Ji, J.F. (2011). Analysis of splenic hilar lymph node metastasis in advanced gastric cancer and dissection techniques. Zhonghua wei Chang wai ke za zhi= Chinese Journal of Gastrointestinal Surgery, 14(8), 589–592.

31. Xing, X., Jia, S., Wu, J., Feng, Q., Dong, B., Li, B., Jia, Y., Shan, F., Li, Y., Zhang, Y., & others (2017). Clonality analysis of synchronous gastro-oesophageal junction carcinoma and distal gastric cancer by whole-exome sequencing. The Journal of Pathology, 243(2), 165–175.

32. Fu, T., Bu, Z.D., Li, Z.Y., Zhang, L.H., Wu, X.J., Wu, A.W., Shan, F., Ji, X., Dong, Q.S., & Ji, J.F. (2015). Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials. BMC cancer, 15, 1–9.

33. Li, Z., Shan, F., Zhang, L., Bu, Z., Wu, A., Wu, X., Zong, X., Li, S., Ji, X., & Ji, J. (2014). Preoperative chemotherapy with a trastuzumab-containing regimen for a patient with gastric cancer and hepatic metastases. Genet Mol Res, 13(4), 10952–10957.

34. Li, Z., Ao, S., Bu, Z., Wu, A., Wu, X., Shan, F., Ji, X., Zhang, Y., Xing, Z., & Ji, J. (2016). Clinical study of harvesting lymph nodes with carbon nanoparticles in advanced gastric cancer: a prospective randomized trial. World Journal of Surgical Oncology, 14, 1–8.

35. Li, Z., Shan, F., Wang, Y., Li, S., Jia, Y., Zhang, L., Yin, D., & Ji, J. (2016). Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: safety and short-term oncologic results. Surgical Endoscopy, 30, 4265–4271.

36. Xue, K., Shan, F., & JI, J. (2013). Meta-analysis of the safety of Yangzhengxiaoji capsule for the treatment of cancer and precancerosis. Chinese Journal of Clinical Oncology, 1318–1323.

37. Li, Z., Wang, Y., Shan, F., Ying, X., Wu, Z., Xue, K., Miao, R., Zhang, Y., & Ji, J. (2018). ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system. Gastric Cancer, 21, 977–987.

38. Li, Z., Shan, F., Ying, X., Zhang, L., Ren, H., Li, S., Jia, Y., Miao, R., Xue, K., Li, Z., & others (2018). Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer: study protocol for a randomised phase II trial. BMJ open, 8(8), e021633.

39. Wu, A., Shan, F., Xue, W., Dong, B., Zhang, L., Li, Z.Y., Bu, Z., Wu, X., Zong, X., & Ji, J. (2011). Clinicopathological observation of gastric cancer with pathological complete response following neoadjuvant chemotherapy. Zhonghua wei Chang wai ke za zhi= Chinese Journal of Gastrointestinal Surgery, 14(8), 596–598.

40. Li, Z., Ying, X., Shan, F., & Ji, J. (2018). The association of garlic with Helicobacter pylori infection and gastric cancer risk: A systematic review and meta-analysis. Helicobacter, 23(5), e12532.

41. Li, Z., Li, S., Bu, Z., Zhang, L., Wu, X., Shan, F., Jia, Y., Ji, X., & Ji, J. (2018). The effect of preoperative treatments on lymph node counts after total gastrectomy in esophagogastric adenocarcinoma. Journal of Surgical Oncology, 118(4), 657–663.

42. Ji, J.f., & Shan, F. (2011). Comprehensive therapy of gastric carcinoma. Zhonghua wai ke za zhi [Chinese journal of surgery], 49(3), 193–197.

43. Li, Z., Shan, F., Ying, X., Xue, K., & Ji, J. (2018). Laparoscopic versus open gastrectomy for elderly local advanced gastric cancer patients: study protocol of a phase II randomized controlled trial. BMC cancer, 18, 1–8.

44. Miao, R., Qu, J., Li, Z., Wang, D., Yu, J., Zang, W., Li, Y., Liu, F., Zhang, J., Song, W., & others (2018). Anatomical variation of infra-pyloric artery origination: a prospective multicenter observational study (IPA-origin). Chinese Journal of Cancer Research, 30(5), 500.

45. Li, Z., Wang, Y., Ying, X., Shan, F., Wu, Z., Zhang, L., Li, S., Jia, Y., Ren, H., & Ji, J. (2019). Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: a propensity score-matched analysis. BMC cancer, 19, 1–10.

46. Xing, X., Guo, J., Ding, G., Li, B., Dong, B., Feng, Q., Li, S., Zhang, J., Ying, X., Cheng, X.,… Shan, F., & others (2018). Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology, 7(3): e1356144.

47. Wang, Y., Li, Z., Shan, F., Zhang, L., Li, S., Jia, Y., Chen, Y., Xue, K., Miao, R., Gao, X., & others (2018). Comparison of the safety and the costs between laparoscopic assisted or totally laparoscopic uncut Roux-en-Y and BillrothII (+ Braun reconstruction–a single center prospective cohort study. Zhonghua wei Chang wai ke za zhi= Chinese Journal of Gastrointestinal Surgery, 21(3), 312–317.

48. JI, J., & Shan, F. (2018). Opportunities and challenges for the progress of Chinese gastric cancer surgery. Chinese Journal of Digestive Surgery, 18–21.

49. Wang, Z., Tang, L., LI, Z., LI, X., FU, J., Shan, F., Zhang, Y., Sun, Y., & JI, J. (2018). Application value of multi-detector computed tomography evaluating the clinical staging of adenocarcinoma of the esophagogastric junction after neoadjuvant chemotherapy. Chinese Journal of Digestive Surgery, 861–868.

50. Zhao, Z., LI, S., LI, Z., Zhang, L., Shan, F., Jia, Y., Xue, K., LI, Z., Miao, R., & JI, J. (2018). Impact of neoadjuvant therapy on the number of harvested lymph nodes in D2 radical resection of the proximal locally advanced gastric cancer. Chinese Journal of Digestive Surgery, 372–376.

51. Li, Z., Shan, F., Ying, X., Zhang, Y., Jian-Yu, E., Wang, Y., Ren, H., Su, X., & Ji, J. (2019). Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized clinical trial. JAMA surgery, 154(12), 1093–1101.

52. Liu, D., Jiang, T., Wang, Y., Miao, R., Shan, F., & Li, Z. (2019). Surgical skill assessment on in-vivo clinical data via the clearness of operating field. In Medical Image Computing and Computer Assisted Intervention–MICCAI 2019: 22nd International Conference, Shenzhen, China, October 13–17, 2019, Proceedings, Part V 22 (pp. 476–484).

53. Wu, Z., Cheng, H., Shan, F., Ying, X., Miao, R., Dong, J., Sun, Y., Xu, A., Zhou, Y., Wang, Y., & others (2019). In-hospital mortality risk model of gastric cancer surgery: Analysis of a nationwide institutional-level database with 94,277 Chinese patients. Frontiers in Oncology, 9, 846.

54. Li, Z., Li, S., Ying, X., Zhang, L., Shan, F., Jia, Y., & Ji, J. (2020). The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy. Gastric Cancer, 23, 540–549.

55. Shan, F., Li, Z., & Ji, J. (2020). Laparoscopic Gastrectomy After Neoadjuvant Chemotherapy—Reply. JAMA surgery, 155(5), 450–451.

56. Li, Z., Gao, X., Peng, X., May Chen, M.J., Li, Z., Wei, B., Wen, X., Wei, B., Dong, Y., Bu, Z., & others (2020). Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy. Science advances, 6(9), eaay4211.

57. Tang, L., Sun, Y., Li, Z., Zhang, X., Cao, K., Li, X., Shan, F., & Ji, J. (2015). Correlation of diffusion weighted MR imaging with the prognosis of local advanced gastric carcinoma after neoadjuvant chemotherapy. Zhonghua wei Chang wai ke za zhi= Chinese Journal of Gastrointestinal Surgery, 18(3), 221–226.

58. Li, Z., Xiao, Q., Wang, Y., Wang, W., Li, S., Shan, F., Zhou, Z., & Ji, J. (2020). A modified ypTNM staging system–development and external validation of a nomogram predicting the overall survival of gastric cancer patients received neoadjuvant chemotherapy. Cancer management and research, 2047–2055.

59. Shan, F., Gao, C., Li, X.L., Li, Z.Y., Ying, X.J., Wang, Y.K., Li, S.X., Ji, X., & Ji, J.F. (2020). Short-and long-term outcomes after laparoscopic versus open gastrectomy for elderly gastric cancer patients: A systematic review and meta-analysis. Journal of Laparoendoscopic & Advanced Surgical Techniques, 30(7), 713–722.

60. Wang, Q., Wu, Z., Shi, J., Hou, S., Shan, F., Li, S., Zhang, Y., Li, Z., & Ji, J. (2022). Omitting nasogastric tube placement after gastrectomy does not enhance postoperative recovery: a propensity score matched analysis. Langenbeck's Archives of Surgery, 1–10.

61. Shi, J., Wu, Z., Wang, Q., Zhang, Y., Shan, F., Hou, S., Ying, X., Huangfu, L., Li, Z., & Ji, J. (2020). Clinical predictive efficacy of C-reactive protein for diagnosing infectious complications after gastric surgery. Therapeutic Advances in Gastroenterology, 13, 1756284820936542.

62. Ji, J., & Shan, F. (2015). Pay more attention to the standardized oncologic assessment of gastric cancer prior to starting therapy. Zhonghua wei Chang wai ke za zhi= Chinese Journal of Gastrointestinal Surgery, 18(2), 104–107.

63. Wu, Z., Shi, J., Shan, F., Li, Z., & Ji, J. (2017). Postoperative complication registration in gastric cancer surgery from 2005 to 2016: a learning curve in our institution. Zhonghua wei Chang wai ke za zhi= Chinese Journal of Gastrointestinal Surgery, 20(2), 177–183.

64. Li, Z., Wu, X., Gao, X., Shan, F., Ying, X., Zhang, Y., & Ji, J. (2020). Development and validation of an artificial neural network prognostic model after gastrectomy for gastric carcinoma: An international multicenter cohort study. Cancer Medicine, 9(17), 6205–6215.

65. Liu, D., Wei, Y., Jiang, T., Wang, Y., Miao, R., Shan, F., & Li, Z. (2020). Unsupervised surgical instrument segmentation via anchor generation and semantic diffusion. In Medical Image Computing and Computer Assisted Intervention–MICCAI 2020: 23rd International Conference, Lima, Peru, October 4–8, 2020, Proceedings, Part III 23 (pp. 657–667).

66. Liu, D., Jiang, T., Wang, Y., Miao, R., Shan, F., & Li, Z. (2020). Clearness of operating field: a surrogate for surgical skills on in vivo clinical data. International Journal of Computer Assisted Radiology and Surgery, 15, 1817–1824.

67. Wang, Y., Liu, Z., Shan, F., Ying, X., Zhang, Y., Li, S., Jia, Y., Li, Z., & Ji, J. (2020). Optimal timing to surgery after neoadjuvant chemotherapy for locally advanced gastric cancer. Frontiers in Oncology, 10, 613988.

68. Li, Z., Wu, X., Gao, X., Shan, F., Ying, X., Zhang, Y., & Ji, J. (2021). Development and validation of a novel staging system integrating the number and location of lymph nodes for gastric adenocarcinoma. British Journal of Cancer, 124(5), 942–950.

69. Liu, Z., Wang, Y., Shan, F., Ying, X., Zhang, Y., Li, S., Jia, Y., Li, Z., & Ji, J. (2021). 5-FU-based doublet regimen in patients receiving perioperative or postoperative chemotherapy for locally advanced gastric cancer: when to start and how long should the regimen last?. Cancer Management and Research, 147–161.

70. Xing, J., Wang, Y., Shan, F., Li, S., Jia, Y., Ying, X., Zhang, Y., Li, Z., & Ji, J. (2021). Comparison of totally laparoscopic and laparoscopic assisted gastrectomy after neoadjuvant chemotherapy in locally advanced gastric cancer. European Journal of Surgical Oncology, 47(8), 2023–2030.

71. Hong, F., Wang, Y., Zhang, Y., Li, S., Shan, F., Jia, Y., Li, Z., & Ji, J. (2021). Comparison of the short-term outcomes of laparoscopic and open total or proximal gastrectomy using the transorally inserted anvil (OrVil TM) for the proximal reconstruction: a propensity score matching analysis. Langenbeck's Archives of Surgery, 406, 651–658.

72. Wang, Y., Lei, X., Liu, Z., Shan, F., Ying, X., Li, Z., & Ji, J. (2021). Short-term outcomes of laparoscopic versus open total gastrectomy after neoadjuvant chemotherapy: a cohort study using the propensity score matching method. Journal of Gastrointestinal Oncology, 12(2), 237.

73. Liu, D., Li, Q., Jiang, T., Wang, Y., Miao, R., Shan, F., & Li, Z. (2021). Towards unified surgical skill assessment. In Proceedings of the IEEE/CVF conference on computer vision and pattern recognition (pp. 9522–9531).

74. Liu, Z., Wang, Y., Shan, F., Ying, X., Zhang, Y., Li, S., Jia, Y., Miao, R., Xue, K., Li, Z., & others (2021). Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment. BMC gastroenterology, 21, 1–17.

75. LI, S., LI, Z., LI, S., ZHANG, L., Shan, F., JIA, Y., XUE, K., MIAO, R., LI, Z., YAN, C., & others (2019). Application value of carbon nanoparticle labeled lymph node staining in radical resection of adenocarcinoma of esophagogastric junction with preoperative chemoradiotherapy. Chinese Journal of Digestive Surgery, 780–784.

76. Liu, Z., Wang, Y., Shan, F., Ying, X., Zhang, Y., Li, S., Jia, Y., Miao, R., Xue, K., Li, Z., & others (2021). Treatment switch in poor responders with locally advanced gastric cancer after neoadjuvant chemotherapy. Annals of Surgical Oncology, 28, 8892–8907.

77. Wang, Y., Liu, Z., Shan, F., Ying, X., Zhang, Y., Li, S., Jia, Y., Jiang, Z., Yang, X., Li, B., & others (2021). Short-term outcomes after totally laparoscopic total gastrectomy with esophagojejunostomy constructed by π-shaped method versus overlap method. Journal of Surgical Oncology, 124(8), 1329–1337.

78. Shi, J., Wu, Z., Wu, X., Shan, F., Zhang, Y., Ying, X., Li, Z., & Ji, J. (2022). Early diagnosis of anastomotic leakage after gastric cancer surgery via analysis of inflammatory factors in abdominal drainage. Annals of Surgical Oncology, 1–12.

79. Jinyao, S., Zhouqiao, W., Wu, X., Fei, S., Zhang, Y., Xiangji, Y., Li, Z., & Jiafu, J. (2021). ASO Visual Abstract: Early Diagnosis of Anastomotic Leakage After Gastric Cancer Surgery via Analysis of Inflammatory Factors in Abdominal Drainage. Annals of Surgical Oncology, 28, 753–753.

80. Zhang, Y., Li, S., Yan, C., Chen, J., & Shan, F. (2021). Perioperative use of glucocorticoids and intraoperative hypotension may affect the incidence of postoperative infection in patients with gastric cancer: A retrospective cohort study. Cancer Management and Research, 7723–7734.

81. Liu, Z., Wang, Y., Shan, F., Ying, X., Zhang, Y., Li, S., Jia, Y., Miao, R., Xue, K., Li, Z., & others (2021). Duration of perioperative chemotherapy in locally advanced gastric cancer: a “l(fā)ess is more” question when ypN0 is achieved. Frontiers in Oncology, 11, 775166.

82. Liu, Z., Yinkui, W., Fei, S., Xiangji, Y., Zhang, Y., Li, S., Yongning, J., Rulin, M., Kan, X., Li, Z., & others (2021). ASO Visual Abstract: Treatment Switch for Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 28, 706–707.

83. Ji, J., Shi, L., Ying, X., Lu, X., Shan, F., & Wang, H. (2021). Associations of centralization with health care quality for gastric cancer patients receiving gastrectomy in China. Chinese Journal of Cancer Research, 33(6), 659.

84. Shi, J., Wu, Z., Wu, X., Shan, F., Zhang, Y., Ying, X., Li, Z., & Ji, J. (2022). Early diagnosis of anastomotic leakage after colorectal cancer surgery using an inflammatory factors-based score system. BJS open, 6(3), zrac069.

85. Li, Z., Guan, G., Liu, Z., Li, J., Ying, X., Shan, F., & Li, Z. (2022). Predicting peritoneal carcinomatosis of gastric cancer: A simple model to exempt low-risk patients from unnecessary staging laparoscopy. Frontiers in Surgery, 9, 916001.

86. Ji, J., Shi, L., Ying, X., Lu, X., & Shan, F. (2022). Associations of annual hospital and surgeon volume with patient outcomes after gastrectomy: a systematic review and meta-analysis. Annals of surgical oncology, 29(13), 8276–8297.

87. Li, S., Ying, X., Shan, F., Jia, Y., Li, Z., Xue, K., Miao, R., Wang, Y., Bu, Z., Su, X., & others (2022). Laparoscopic vs. open lower mediastinal lymphadenectomy for Siewert type II/III adenocarcinoma of esophagogastric junction: An exploratory, observational, prospective, IDEAL stage 2b cohort study (CLASS-10 study). Chinese Journal of Cancer Research, 34(4), 406.

88. Guan, G., Li, Z., Wang, Q., Ying, X., Shan, F., & Li, Z. (2022). Risk factors associated with peritoneal carcinomatosis of gastric cancer in staging laparoscopy: A systematic review and meta-analysis. Frontiers in Oncology, 12, 955181.

89. Tang, X., Li, M., Wu, X., Guo, T., Zhang, L., Tang, L., Jia, F., Hu, Y., Zhang, Y., Xing, X., & others (2022). Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer. Oncoimmunology, 11(1), 2135819.

90. Chen, J.B., Liu, Z.N., Wang, Y.K., Shan, F., Li, S.X., Jia, Y.N., Xue, K., Miao, R.L., Li, Z.M., Wu, Z.Q., & others (2022). The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer. Frontiers in Oncology, 12, 956706.

91. Wang, Y., Lei, X., Shan, F., Li, S., Jia, Y., Miao, R., Xue, K., Li, Z., Ji, J., & Li, Z. (2022). Safety and short-term outcomes of gastrectomy after preoperative chemotherapy plus immunotherapy versus preoperative chemotherapy: a retrospective cohort study. BMC cancer, 22(1), 1306.

92. Lei, X., Wang, Y., Shan, F., Li, S., Jia, Y., Miao, R., Xue, K., Li, Z., Ji, J., & Li, Z. (2022). Short-and long-term outcomes of laparoscopic versus open gastrectomy in patients with gastric cancer: a systematic review and meta-analysis of randomized controlled trials. World Journal of Surgical Oncology, 20(1), 405.

93. Chen, X., Wu, Z., He, Y., Hao, Z., Wang, Q., Zhou, K., Zhou, W., Wang, P., Shan, F., Li, Z., & others (2023). Accurate and Rapid Detection of Peritoneal Metastasis from Gastric Cancer by AI-Assisted Stimulated Raman Molecular Cytology. Advanced Science, 10(21), 2300961.

94. Jia, Y., Zhu, H., Pang, F., Shan, F., Li, S., Wang, D., Li, L., Ma, T., & Li, Z. (2020). Chromosomal instability of circulating tumor DNA predicts response to neoadjuvant chemotherapy in gastric cancer. Cancer Research, 80(16_Supplement), 1991–1991.

95. Jia, Y., Yuan, H., Xin, Y., Pang, F., Shan, F., Li, S., Zhu, H., & Li, Z. (2022). Loss-of-function mutations in ACVR2A are correlated with microsatellite instability in gastric and colorectal cancer. Cancer Research, 82(12\_Supplement), 5752–5752.

96. Jia, Y., Zhu, H., Pang, F., Shan, F., Li, S., Dong, L., Ma, T., & Li, Z. (2020). Tumor mutation burden combined with tumor markers as predictive prognostic biomarkers for neoadjuvant chemotherapy in patients with gastric cancer. Cancer Research, 80(16\_Supplement), 6467–6467.

97. Li, Z., Jia, Y., Zhu, H., Xing, X., Pang, F., Shan, F., Li, S., Wang, D., Zhao, F., Ma, T., & others (2021). Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy. Gastric Cancer, 24(6), 1342–1354.

98. Jia, Y., Xin, Y., Yuan, H., Pang, F., Shan, F., Li, S., Zhu, H., & Li, Z. (2022). Comprehensive analysis of POLE/POLD1 variants, MMR deficient/MSI, and tumor mutational burden in Chinese population. Cancer Research, 82(12\_Supplement), 5751–5751.

99. Fei, S., Ziyu, L., Lianhai, Z., Shuangxi, L., Yongning, J., Rulin, M., Xue, K., Zhemin, L., Gao, X., Wang, Y., & others (2017). The Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) gastric cancer TNM staging system explanation and elaboration. Chin J Pract Surg, 37(01), 15–17.

100. Yan, C., Shan, F., Ying, X., & Li, Z. (2023). Global burden prediction of gastric cancer during demographic transition from 2020 to 2040. Chinese Medical Journal, 136(4), 397–406.

101. Wang, Y., Hong, F., Li, S., Shan, F., Jia, Y., Miao, R., Li, Z., Li, Z., & Ji, J. (2023). Exploration and optimization of surgical techniques for laparoscopic transhiatal lower mediastinal lymph node dissection for adenocarcinoma of esophagogastric junction: A prospective IDEAL 2a study with qualitative design. Chinese Journal of Cancer Research, 35(2), 163.

102. Shan, F., Li, Z., Hirst, A., & McCulloch, P. (2019). Using the learning curve and Bayesian analysis to decide when surgeons are ready to randomise. In TRIALS.

103. Yu, J., Shan, F., Hirst, A., McCulloch, P., Li, Y., & Sun, X. (2021). Identifying research waste from surgical research: a protocol for assessing compliance with the IDEAL framework and recommendations. BMJ surgery, interventions, & health technologies, 3(1).

104. Lei, X., Wang, Y., Shan, F., Li, S., Jia, Y., Miao, R., Xue, K., Li, Z., Ji, J., & Li, Z. (2023). Efficacy and safety of preoperative immunotherapy alone followed by surgery in the treatment of advanced gastric cancer with MSI-H/dMMR or EBV-positive. Journal of the Chinese Medical Association, 86(8), 717–724.

105. Li, B., Miao, R., Shan, F., Li, S., Jia, Y., Xue, K., Li, Z., Ying, X., Pang, F., Zhang, Y., & others (2023). Efficacy of chemotherapy versus surgery as initial treatment for gastric cancer with positive peritoneal cytology. World Journal of Surgical Oncology, 21(1), 204.

106. Wang, Y., Li, B., Shan, F., Li, S., Xue, K., Miao, R., & Li, Z. (2024). A modified esophagogastric reconstruction method after laparoscopic proximal gastrectomy: a technical note with video vignette. Asian Journal of Surgery, 47(1), 502–504.

107. Yinkui, W., Ziyu, L., Fei, S., Rulin, M., Kan, X., Zhemin, L., Chao, G., Nan, C., Xiangyu, G., Shen, L., & others (2018). Current status of diagnosis and treatment of early gastric cancer in China–Data from China Gastrointestinal Cancer Surgery Union. Chinese Journal of Gastrointestinal Surgery, 168–174.

108. Wang, Y., Tang, L., Ying, X., Li, J., Shan, F., Li, S., Jia, Y., Xue, K., Miao, R., Li, Z., & others (2024). Pre-and post-treatment double-sequential-point dynamic radiomic model in the response prediction of gastric cancer to neoadjuvant chemotherapy: 3-year survival analysis. Annals of Surgical Oncology, 31(2), 774–782.

109. LIU, Y., LI, X., LI, X., LI, J., HE, M., Shan, F., CAI, P., LI, Z., & TANG, L. (2022). Clinical value of CT-based three-section formula in identification of Siewert types of adeno-carcinoma of esophagogastric junction. Chinese Journal of Digestive Surgery, 135–142.

110. Li, B., Wang, Y., Li, B., Shan, F., & Li, Z. (2024). Short-term outcomes and long-term quality of life of reconstruction methods after proximal gastrectomy: a systematic review and meta-analysis. BMC cancer, 24(1), 56.

111. Li, B., Wang, Y., Wu, Z., Shan, F., Li, S., Jia, Y., Miao, R., Li, Z., Xue, K., Yan, C., & others (2024). Safety and short-term outcomes of a modified valvuloplastic esophagogastrostomy versus gastric tube anastomosis after laparoscopy-assisted proximal gastrectomy: a retrospective cohort study. Surgical Endoscopy, 38(3), 1523–1532.

112. Du, Z.J., Wu, Z.Q., Shan, F., Li, Y.A., Pang, F., Li, Z.Y., & Ji, J.F. (2023). Comparison of safety of total laparoscopic versus laparoscopic-assisted radical gastrectomy for distal gastric cancer in older patients. Zhonghua wei Chang wai ke za zhi= Chinese Journal of Gastrointestinal Surgery, 26(2), 167–174.

113. Li, S., Xue, K., Dai, H.M., Wang, Y.K., Shan, F., Li, Z.Y., & Ji, J.F. (2023). Effects of laparoscopic hyperthermic intraperitoneal perfusion chemotherapy combined with intraperitoneal and systemic chemotherapy treatment in patients with untreated gastric cancer with peritoneal metastasis. Zhonghua wei Chang wai ke za zhi= Chinese Journal of Gastrointestinal Surgery, 26(5), 442–447.

114. Wu, Z., Gu, T., Xiong, C., Shi, J., Wang, J., Guo, T., Xing, X., Pang, F., He, N., Miao, R., & others (2024). Genomic characterization of peritoneal lavage cytology-positive gastric cancer. Chinese Journal of Cancer Research, 36(1), 66.

115. Wei, T., Wu, Z., Chen, Y., Li, Y., Pang, F., Shan, F., Li, Z., & Ji, J. (2024). Comparison of uncut Roux-en-Y anastomosis and Billroth-II with Braun anastomosis after distal gastrectomy. Frontiers in Surgery, 11, 1390876.

116. Gu, T., Wang, Y., Wu, Z., He, N., Li, Y., Shan, F., Li, Z., & Ji, J. (2024). Feasibility and long-term survival of proximal gastrectomy after neoadjuvant therapy for locally advanced proximal gastric cancer: A propensity-score-matched analysis. Chinese Medical Journal, 10–1097.

117. Wang, Y., Lei, X., Shan, F., Li, S., Jia, Y., Miao, R., Xue, K., Li, Z., Ji, J., & Li, Z. (2024). Long-term outcomes of laparoscopic versus open total gastrectomy in patients with advanced gastric cancer after neoadjuvant chemotherapy: a retrospective cohort study. BMC cancer, 24(1), 1074.

醫(yī)學(xué)博士，主任醫(yī)師，北京市優(yōu)秀人才培養(yǎng)資助青年骨干?，F(xiàn)任北京大學(xué)腫瘤醫(yī)院胃腸腫瘤中心一病區(qū)副主任（主持工作）。兼任國家腫瘤質(zhì)控中心胃癌質(zhì)控專家委員會委員兼秘書、中國抗癌協(xié)會青年理事會常務(wù)理事、中國抗癌協(xié)會胃癌專業(yè)委員會委員、中國抗癌協(xié)會手術(shù)安全與質(zhì)量控制專委會常務(wù)委員兼秘書長、中國抗癌協(xié)會腫瘤大數(shù)據(jù)與真實世界研究專業(yè)委員會常務(wù)委員、中國臨床腫瘤學(xué)會青年委員、國際胃癌學(xué)會會員。主要研究方向包括胃癌的微創(chuàng)外科與圍術(shù)期綜合治療、外科臨床研究方法學(xué)框架的開發(fā)與應(yīng)用。在手術(shù)視頻資料分析、胃癌專科疾病數(shù)據(jù)庫建設(shè)與質(zhì)量控制等多個臨床實踐的數(shù)據(jù)化工作方面具有豐富經(jīng)驗。在Nature Medcine、JAMA Surgery、Gastric Cancer等領(lǐng)域內(nèi)重要期刊累計發(fā)表各類學(xué)術(shù)文章120余篇，發(fā)表論文在“谷歌學(xué)術(shù)”總引用1970余次（h指數(shù)24）。獲…